Lipoprotein(a) is a Promising Residual Risk Factor for Long-Term Clinical Prognosis in Peripheral Arterial Disease
Author:
Affiliation:
1. Department of Cardiovascular Surgery, Cardiovascular Hospital of Central Japan (Kitakanto Cardiovascular Hospital)
2. Department of Cardiovascular Medicine, Cardiovascular Hospital of Central Japan (Kitakanto Cardiovascular Hospital)
Publisher
The Editorial Committee of Annals of Vascular Diseases
Subject
Pharmaceutical Science
Link
https://www.jstage.jst.go.jp/article/avd/15/3/15_oa.22-00046/_pdf
Reference30 articles.
1. 1) Berglund L, Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 2004; 24: 2219-26.
2. 2) Kamstrup PR, Benn M, Tybjaerg-Hansen A, et al. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008; 117: 176-84.
3. 3) Kumakura H, Fujita K, Kanai H, et al. High-sensitivity C-reactive protein, lipoprotein(a) and homocysteine are risk factors for coronary artery disease in Japanese patients with peripheral arterial disease. J Atheroscler Thromb 2015; 22: 344-54.
4. 4) Drozda JP Jr, Ferguson TB Jr, Jneid H, et al. 2015 ACC/AHA focused update of secondary prevention lipid performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures. J Am Coll Cardiol 2016; 67: 558-87.
5. 5) Mora S, Wenger NK, Demicco DA, et al. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation 2012; 125: 1979-87.
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Secondary Prevention and Extreme Cardiovascular Risk Evaluation (SEVERE-1), Focus on Prevalence and Associated Risk Factors: The Study Protocol;High Blood Pressure & Cardiovascular Prevention;2023-11-30
2. Lipoprotein(a)—60 Years Later—What Do We Know?;Cells;2023-10-17
3. Predictive Value of the Lipoprotein(a) to Prealbumin Ratio and of the NT-proBNP to LVEF Ratio for Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome;The Heart Surgery Forum;2023-10-07
4. Are we seeing the light at the end of the tunnel for high lipoprotein(a)? Lipoprotein(a);European Atherosclerosis Journal;2023-04-20
5. Lipoprotein(a): Cardiovascular Disease, Aortic Stenosis and New Therapeutic Option;International Journal of Molecular Sciences;2022-12-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3